2002
DOI: 10.1016/s0301-472x(02)00867-6
|View full text |Cite
|
Sign up to set email alerts
|

Determination of bone marrow–derived endothelial progenitor cell significance in angiogenic growth factor–induced neovascularization in vivo

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

7
150
0
2

Year Published

2003
2003
2016
2016

Publication Types

Select...
5
4

Relationship

0
9

Authors

Journals

citations
Cited by 242 publications
(160 citation statements)
references
References 24 publications
7
150
0
2
Order By: Relevance
“…34 On the other hand, other reports have shown that the existence of circulating BM endothelial progenitor cells can restore blood flow to ischemic animals leading to the concept of 'therapeutic adult vasculogenesis' that may explain the recruitment of ECs to various target organs such as BM, where they might contribute to the in situ neo-vascularization. [33][34][35][36][37][38][39][40] This phenomenon may sustain a physiological angiogenesis process, which is probably essential for tissue repair, remodeling, and regeneration and these are in line with our results, since the number of CFU-En from patients in remission phase positively correlated with the frequency of BM CFU-GM colonies, possibly suggesting a parallel process of bone marrow reconstitution. [33][34][35][36][37][38][39][40] In conclusion, Endothelial colonies in non-Hodgkin's lymphomaour in vitro data have shown that NHL patients in remission state have higher numbers of CFU-En than that of newly diagnosed subjects, thus providing a rationale for further investigating the effects of different cytostatic drugs on endothelial cells growth and function.…”
Section: Discussionsupporting
confidence: 87%
See 1 more Smart Citation
“…34 On the other hand, other reports have shown that the existence of circulating BM endothelial progenitor cells can restore blood flow to ischemic animals leading to the concept of 'therapeutic adult vasculogenesis' that may explain the recruitment of ECs to various target organs such as BM, where they might contribute to the in situ neo-vascularization. [33][34][35][36][37][38][39][40] This phenomenon may sustain a physiological angiogenesis process, which is probably essential for tissue repair, remodeling, and regeneration and these are in line with our results, since the number of CFU-En from patients in remission phase positively correlated with the frequency of BM CFU-GM colonies, possibly suggesting a parallel process of bone marrow reconstitution. [33][34][35][36][37][38][39][40] In conclusion, Endothelial colonies in non-Hodgkin's lymphomaour in vitro data have shown that NHL patients in remission state have higher numbers of CFU-En than that of newly diagnosed subjects, thus providing a rationale for further investigating the effects of different cytostatic drugs on endothelial cells growth and function.…”
Section: Discussionsupporting
confidence: 87%
“…[33][34][35][36][37][38][39][40] This phenomenon may sustain a physiological angiogenesis process, which is probably essential for tissue repair, remodeling, and regeneration and these are in line with our results, since the number of CFU-En from patients in remission phase positively correlated with the frequency of BM CFU-GM colonies, possibly suggesting a parallel process of bone marrow reconstitution. [33][34][35][36][37][38][39][40] In conclusion, Endothelial colonies in non-Hodgkin's lymphomaour in vitro data have shown that NHL patients in remission state have higher numbers of CFU-En than that of newly diagnosed subjects, thus providing a rationale for further investigating the effects of different cytostatic drugs on endothelial cells growth and function. However, based on results on BM hematopoietic colony assays and on previously published papers the data here presented seem to suggest that human bone marrow endothelial cells could also be involved in mechanisms, which are different from tumor angiogenesis, such as hematopoietic cell preservation and physiological repair after chemotherapy.…”
Section: Discussionsupporting
confidence: 87%
“…20 EPCs, primarily described in the landmark observation of Asahara et al, 21 represent a population of bone marrow-derived, CD34-, VEGF receptor-2 (VEGFR-2 or kinase-insert domain receptor [KDR])-, AC133-positive cells 22 that have the ability to differentiate into endothelial cells and thus, make a significant contribution to new blood vessel formation. 23 It has long been thought that EPCs could be cultured from peripheral blood mononuclear cells (PBMCs) on fibronectin and then express receptors for LDL and lectin. 21 However, recent observations indicate that these cultured cells are mainly monocyte/leukocyte-derived entities 24,25 ; nevertheless, they also contribute to angiogenesis by secreting proangiogenic factors and are now referred to as circulating angiogenic cells (CACs).…”
mentioning
confidence: 99%
“…[1][2][3][4][5] The mobilization and differentiation of bone marrow-derived endothelial progenitor cells (EPCs) has recently been shown to be important in this process of adult neovascularization. 6 -10 Evidence suggests that EPCs contribute as much as 25% of endothelial cells (ECs) in newly formed blood vessels, 11 and transplantation of EPCs into patients has been demonstrated to induce blood flow recovery in ischemic limbs 12 and increase myocardial viability after infarction. 13 The number and migratory activity of circulating EPCs has also been shown to inversely correlate with risk factors for coronary artery disease 14 and to serve as a surrogate biological marker for vascular function and cumulative cardiovascular risk.…”
mentioning
confidence: 99%